2025 Highlights
Montefiore Einstein Comprehensive Cancer Center
For more than 50 years, Montefiore Einstein Comprehensive Cancer Center (MECCC) has been at the forefront of cancer research, care, and community engagement. Our mission is to reduce the cancer burden and provide compassionate cancer care for all, notably in the Bronx. Our unique offerings include access to a broad array of innovative new treatments, Phase I clinical trials with a strong developmental therapeutics program, a renowned cell therapy program, numerous options for minimally invasive/robotic surgeries for most cancer types, state-of-the-art radiation technologies, i.e., proton therapy, and many others, including world-class foundational cancer research programs. We are a leading Center for providing cancer screenings to all eligible patients in the Bronx and expanding access to care utilizing unique tools and artificial intelligence to enhance continuity of care and patient communication. We continue to build upon our exceptional training programs and investments in Survivorship Programs with dedicated clinics across most of our Cancer Center locations.
DATA & STATISTICS
MECCC by the numbers
$7M
1,572
160,000+
outpatient visits
560+
physicians, nurse practitioners, physician assistants, and allied health professionals
Team News
Additions to our distinguished faculty
Innovations, Honors, and Achievements
Pioneering the future of cancer treatment & care
Richard S. Ha, MD, Inducted as a Fellow of the Society of Breast Imaging at the Radiological Society of North America
This prestigious honor recognizes the outstanding contributions, clinical excellence, and breast imaging leadership of Dr. Ha, Vice Chair of Radiology Outpatient Imaging Operations and Chief of Community Radiology.
Clinical Trials
Advancing cancer care through clinical trials
We focus on clinical research studies on all types of cancer in our community. All our patients have access to novel cutting-edge agents, interventions, and preventative approaches through our clinical trials. Cancer Center investigators have been busy developing novel trials through our investigator-initiated trials program and conducting multiple studies, including on agents that have been developed through our robust transdisciplinary research programs, translational accelerator mechanisms, and Shared Resources programming with Albert Einstein College of Medicine laboratories.
Highlights from our current 500 clinical research studies include:
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Research Review
Improving cancer care & outcomes through research
We strive to improve cancer care and outcomes through multiple transdisciplinary research programs and initiatives funded by the National Institutes of Health, including the National Cancer Institute, major cancer research foundations, and pharmaceutical companies. Our internationally renowned blood cancer scientists have discovered key drivers of acute myeloid leukemia (AML), breast cancer, and other cancers that arise from abnormal stem cells, which are extremely difficult to eradicate. MECCC is breaking new ground in such areas as cancer dormancy and awakening, stem cells in cancer, disrupted cancer gene regulation and metabolism, correlating environmental exposures to cancer risk and mortality, and understanding the influence of the immune system in shaping the body’s reaction to cancer cells.
Expanding access
Access matters. We are located in the Bronx, the northernmost of the five boroughs that comprise New York City, and we are rapidly expanding the number of locations where people can easily be seen throughout the Tristate area, no matter the level of income, cancer risk, or cancer diagnosis. As of 2025: MECCC has 20 outpatient locations.
Cast your vote
Polls on Doximity close soon. We hope you’ll consider nominating Montefiore Einstein Comprehensive Cancer Center for the U.S. News & World Report Best Hospitals survey.
Contact us
Anne McDarby
Associate Director, Network Program Management
Montefiore Einstein Comprehensive Cancer Center
1-718-862-8840 /ext. 5034
amcdarby@montefiore.org
Andrea Peirce
Assistant Director, Communications
Montefiore Einstein Comprehensive Cancer Center
andrea.peirce@einsteinmed.edu





























































